CMS is testing MA health plan innovations aimed reducing program costs and improving the quality of care being delivered to enrollees.

In Calendar Year (CY) 2024, the VBID Model will test flexibilities for select enrollees by offering certain supplemental benefits, including FDA-approved devices, disease state management programs, reductions in cost-sharing, Part C and D rewards and incentives programs, and a hospice benefit.

This session will examine how the model has been performing to date and the implications for plans and patients moving forward.